Literature DB >> 30458922

Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.

Kathryn L Pepple1, Phoebe Lin2.   

Abstract

The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti-IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30458922      PMCID： PMC6538052          DOI： 10.1016/j.ophtha.2018.05.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


  78 in total

1.  Characterization of autoreactive and bystander IL-17+ T cells induced in immunized C57BL/6 mice.

Authors:  Hong Nian; Dongchun Liang; Aijun Zuo; Ruihua Wei; Hui Shao; Willi K Born; Henry J Kaplan; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

2.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

Review 3.  Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation.

Authors:  Robert A Kastelein; Christopher A Hunter; Daniel J Cua
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

4.  Elevated serum levels of interleukin-17A in uveitis patients.

Authors:  Shayma Jawad; Baoying Liu; Elvira Agron; Robert B Nussenblatt; H Nida Sen
Journal:  Ocul Immunol Inflamm       Date:  2013-08-19       Impact factor: 3.070

Review 5.  Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.

Authors:  Zeyu Chen; Yu Gong; Yuling Shi
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

6.  Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.

Authors:  Cristina Mugheddu; Laura Atzori; Maria Del Piano; Astrid Lappi; Monica Pau; Severino Murgia; Ignazio Zucca; Franco Rongioletti
Journal:  Dermatol Ther       Date:  2017-08-18       Impact factor: 2.851

7.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Authors:  Benjamin M Segal; Cris S Constantinescu; Aparna Raychaudhuri; Lilianne Kim; Rosanne Fidelus-Gort; Lloyd H Kasper
Journal:  Lancet Neurol       Date:  2008-09       Impact factor: 44.182

Review 8.  Th17 cells in human disease.

Authors:  Laura A Tesmer; Steven K Lundy; Sujata Sarkar; David A Fox
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

9.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Authors:  Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Shu Li; Lisa T Dooley; Kenneth B Gordon
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

10.  Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

Authors:  Quan Dong Nguyen; Pauline T Merrill; Glenn J Jaffe; Andrew D Dick; Shree Kumar Kurup; John Sheppard; Ariel Schlaen; Carlos Pavesio; Luca Cimino; Joachim Van Calster; Anne A Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Antoine P Brézin
Journal:  Lancet       Date:  2016-08-16       Impact factor: 79.321
View more
  15 in total

1.  A Second Generation Prostanoid Receptor Antagonist Acting at Multiple Receptor Subtypes.

Authors:  David F Woodward; Jenny W Wang; Clayton S Spada; Robert W Carling; Jose L Martos; Simon Pettit; Jussi Kangasmetsa; L David Waterbury; Matthew Lawrence; Wenzheng Hu; Neil J Poloso
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-26

2.  Poor Control of Sarcoidosis-Related Panuveitis with an Antibody to IL-23.

Authors:  Akshay S Thomas; James T Rosenbaum
Journal:  Ocul Immunol Inflamm       Date:  2019-02-27       Impact factor: 3.070

3.  Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.

Authors:  Chao-Ran Li; Lang Chen; Long-Fei Wang; Bin Yan; You-Ling Liang; Jing Luo
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

Review 4.  Therapeutic Potential of Microvesicles in Cell Therapy and Regenerative Medicine of Ocular Diseases With an Especial Focus on Mesenchymal Stem Cells-Derived Microvesicles.

Authors:  Lina Moallemi Rad; Alexey V Yumashev; Bashdar Mahmud Hussen; Hazha Hadayat Jamad; Soudeh Ghafouri-Fard; Mohammad Taheri; Samaneh Rostami; Vahid Niazi; Mohammadreza Hajiesmaeili
Journal:  Front Genet       Date:  2022-03-29       Impact factor: 4.599

Review 5.  Psoriasis and uveitis.

Authors:  Büşra Köse; Dilek Uzlu; Hidayet Erdöl
Journal:  Int Ophthalmol       Date:  2022-01-19       Impact factor: 2.029

Review 6.  Recent advances of exosomes in immune-mediated eye diseases.

Authors:  Na Li; Lu Zhao; Yankai Wei; Vicki L Ea; Hong Nian; Ruihua Wei
Journal:  Stem Cell Res Ther       Date:  2019-08-30       Impact factor: 6.832

7.  Psoriasis and uveitis: links and risks.

Authors:  Christina Fotiadou; Elizabeth Lazaridou
Journal:  Psoriasis (Auckl)       Date:  2019-08-28

Review 8.  Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review.

Authors:  Carla Gaggiano; Donato Rigante; Gian Marco Tosi; Antonio Vitale; Bruno Frediani; Salvatore Grosso; Claudia Fabiani; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2019-12-10       Impact factor: 2.980

Review 9.  Old and New Challenges in Uveitis Associated with Behçet's Disease.

Authors:  Julie Gueudry; Mathilde Leclercq; David Saadoun; Bahram Bodaghi
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

10.  The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.

Authors:  Neeraj Narula; Achuthan Aruljothy; Emily C L Wong; Ravi Homenauth; Abdul-Aziz Alshahrani; John K Marshall; Walter Reinisch
Journal:  United European Gastroenterol J       Date:  2021-06-02       Impact factor: 4.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.